Dyne Therapeutics, Inc. $DYN Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 12.8% in the second quarter, Holdings Channel.com reports. The fund owned 269,985 shares of the company’s stock after buying an additional 30,700 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Dyne Therapeutics were worth $5,996,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of Dyne Therapeutics during the first quarter worth about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after purchasing an additional 2,886 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after purchasing an additional 366,183 shares during the period. Caxton Associates LLP purchased a new position in Dyne Therapeutics during the 1st quarter worth approximately $157,000. Finally, Creative Planning grew its stake in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after buying an additional 2,797 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Buying and Selling

In related news, insider Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock in a transaction on Friday, September 4th. The shares were sold at an average price of $24.35, for a total value of $91,190.75. Following the transaction, the insider directly owned 163,854 shares in the company, valued at $3,989,844.90. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason Rhodes sold 2,160,516 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director directly owned 428,946 shares in the company, valued at $10,723,650. This represents a 83.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,150,974 shares of company stock valued at $99,697,629 in the last ninety days. Company insiders own 9.46% of the company’s stock.

Dyne Therapeutics Stock Down 16.4%

DYN opened at $20.31 on Wednesday. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The business has a 50 day moving average price of $24.82 and a two-hundred day moving average price of $20.49. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The company has a market cap of $3.79 billion, a PE ratio of -6.10 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Key Stories Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne announced that it will present additional six- and 12-month data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The data will include comparisons with a matched natural-history cohort and updated safety results. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, and Dyne expects topline results in the first quarter of 2027. DYNE-101 also has FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, supporting the potential for an expedited development path. Quiver Quantitative ACHIEVE summary
• Neutral Sentiment: Call-option activity surged, with traders purchasing approximately 20,532 calls versus average daily volume of about 464. This may reflect speculative expectations for a rebound or upcoming data, but options activity does not confirm a fundamental improvement.
• Negative Sentiment: Reports said DYN fell heavily after a rival DM1 drug failed in Phase 3. Investors appear concerned that the setback could signal clinical or commercial risks for the DM1 field, even though Dyne’s own upcoming one-year data have not yet been released. RTT News report on rival DM1 failure
• Negative Sentiment: Several executives, including CEO John Cox, reported stock sales. The transactions were made to cover tax withholding on vested equity awards and were relatively small compared with their remaining holdings, limiting their direct significance, but the cluster of sales may add to cautious sentiment.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. TD Cowen assumed coverage on Dyne Therapeutics in a research note on Friday, June 26th. They issued a “buy” rating for the company. Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research report on Thursday, July 23rd. They set an “overweight” rating on the stock. Royal Bank Of Canada lifted their target price on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Monday, August 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.